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  This case report describes the intralesional application of 
autologous conditioned plasma (ACP) in seven horses as 
treatment of severe tendinitis of the superficial digital flexor 
tendon, deep digital flexor tendon, or desmitis of the inferior 
check ligament. Follow-up data of the horses revealed a 
positive outcome in 10 to 13 months post injury. All horses 
treated with ACP were either performing in their previous 
work-load or were back in full training. Further studies with 
long-term follow-up will have to be performed to support 
these clinical intermediate-term observations.
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Tendon and ligament injuries are among the most common 
musculoskeletal injuries and contribute to a considerable 
economic loss for the equine industry [5,8,10,14]. New 
regenerative therapies are thought to harness the animal’s 
ability to repair the injury site and to reduce scar tissue 
formation [6].
Seven horses of different breeds − 3 mares, 4 geldings, 
aged 4 to 12 years, used as sport and/or pleasure riding horses 
− were included in this study. The horses were presented 
at the clinic and met the following criteria: acute severe 
tendinitis of the superficial digital flexor tendon (SDFT) or 
deep digital flexor tendon (DDFT), or acute desmitis of the 
inferior check ligament (ICL) of one or both forelimbs; no 
treatment prior to admission; and otherwise normal results 
of the clinical examination. All horses were subjected to a 
general examination with whole blood analysis and a 
lameness examination. Tendons and ligaments were 
evaluated ultrasonographically and the damaged tendon/ 
ligament areas were documented, with evaluation of the 
following parameters: the cross sectional area (CSA; cm
2), 
the percentage of the maximum injury zone compared to the 
size of a healthy tendon/ligament (%MIZ), the echogenicity 
score (ES) of the lesion (range: 0 to 4), and the fibre 
alignment score (FAS: range 0 to 4). The FAS was 
determined in the longitudinal view of the lesion [12]. 
Autologous conditioned plasma (ACP) therapy was 
performed in each horse (n = 7) at the day of presentation 
at the clinic (D0), and also after a 2-week interval (D1) in 
horse SDFT 2. Autologous conditioned plasma was 
prepared using a 15 mL ACP double syringe (Arthrex 
GmbH, Germany) according to the manufacturer’s 
instructions. An average of 5 mL of ACP was obtained from 
every 15 mL syringe. At D0, a 1 mL fraction of the ACP was 
analyzed for hematocrit (Hct), platelets and white blood cell 
(WBC) count. After preparation the ACP was injected into 
the tendon/ligament- defect through a 21 gauge needle under 
ultrasonographic control. The injected volume (2 mL to 4 
mL) depended on size and type of the lesion. The horses were 
subjected to stable confinement for 28 days. Thereafter they 
were hand- walked for 15 min each day, with the time 
progressively extended up to one hour in the coming months. 
Follow-up for each horse was obtained twice by clinical and 
ultrasonographic examination in 2 to 3 week intervals (D1 
and D2). Follow-up at 7 to 9 months as well as at 10 to 13 
months (D3) was obtained by phone through questioning of 
the owners, trainers and/or referring veterinarians.
Five horses had acute SDFT lesions (zone 1A-3B) with one 
of them showing bilateral lesions (n = 6 limbs). One horse 
had an ICL injury (zone 2A; n = 1) and one horse presented 
with a core lesion of the DDFT (zone 2A; n = 1). The %MIZ 
of the SDFT lesions (n = 6) ranged from 27.23% to 54.20% 
at D0 and decreased at D1 and D2 in all horses except for 
one horse (SDFT 2) which showed a higher %MIZ at D2 
compared to D1 (Fig. 1). The CSA decreased continuously 
in the SDFT lesions from D0 to D2 in all horses except for 
one horse (SDFT 2) in which it increased between D1 and 
D2 (Fig. 2). The ES and FAS decreased continuously from 174    Rindermann Georg et al.
Fig. 1. The percentage of the maximum injury zone compared to
the healthy tendon/ligament (%MIZ) of the superficial digital 
flexor tendon (SDFT; n = 6 limbs), deep digital flexor tendon 
(DDFT; n = 1 limb) and inferior check ligament (ICL; n = 1 limb) 
at day 0 (D0), D1 and D2 in seven horses. D0: day of presentation,
D1: two to three weeks after D0, D2: two to three weeks after D1.
SDFT 3A and SDFT 3B: different forelimbs of the same horse.
Fig. 2. The cross sectional area (CSA) of superficial digital flexor 
tendon (SDFT; n = 6 limbs), deep digital flexor tendon (DDFT; 
n = 1 limb) and inferior check ligament (ICL; n = 1 limb) at D0, 
D1 and D2 in seven horses. D0: day of presentation, D1: two to
three weeks after D0, D2: two to three weeks after D1. SDFT 3A 
and SDFT 3B: different forelimbs of the same horse.
D0 (ES: 2 to 3; FAS: 1 to 3) to D2 (ES: 0 to 1; FAS: 0 to 1) 
in all horses except for horse SDFT 2, which showed an 
increase in ES between D1 (ES:1) and D2 (ES:2), and horse 
SDFT 3B which had an unchanged FAS between D0 and D2. 
The %MIZ for the DDFT lesion (n = 1) was 53.10% at D0. 
The %MIZ for the ICL lesion (n = 1) was 42.80% at D0. The 
%MIZ of the DDFT- and ICL-lesions decreased till D2 (Fig. 
1). The CSA decreased continuously in DDFT- and ICL- 
lesions from D0 to D2 (Fig. 2). The ES improved from D0 
(ES:2) to D2 (ES:1). The FAS improved for the DDFT lesion 
from D0 (FAS:3) to D2 (FAS:2) and the ICL- lesion from 
D0 (FAS:1) to D2 (FAS:0). Follow-up of all horses at 7 to 
9 months post injury and at D3 revealed a positive outcome 
with all horses either performing at their previous work-load 
or were back in full training. No horse experienced re-injury. 
Whole blood and ACP analysis (all horses) revealed that 
platelet counts were on average 1.3-fold higher in ACP 
compared to whole blood. The platelet count in ACP ranged 
from 160 × 10
9 platelets/L to 197 × 10
9 platelets/L, compared 
to the platelet blood values ranging from 115 × 10
9 platelets/ 
L to 173 × 10
9 platelets/L. On average, the WBC count was 
10.92-fold lower in ACP compared to whole blood. The 
WBC count in ACP ranged from 0.44 × 10
9 cells/L to 1.58 
× 10
9 cells/L compared to WBC values in whole blood which 
ranged from 6.41 × 10
9 cells/L to 11 × 10
9 cells/L. The Hct 
was 3.26 × 10
3-fold lower in ACP compared to whole blood. 
The Hct count in ACP ranged from 0% to 0.01% compared 
to that of whole blood which ranged from 30% to 36%.
Tendinitis and desmitis result in a considerable economic 
loss to the equine industry due to decreased performance, 
prolonged rehabilitation, recurrent injuries and early 
retirement. Treatment methods that induce the regeneration 
of healthy tendon tissue, i.e. restoration of the tendon’s 
normal structural architecture and biomechanical function 
rather than formation of scar tissue should therefore decrease 
the risk of re-injury [6]. New regenerative treatment options 
are thought to recapitulate processes taking place during 
embryonic development, with temporal and spatial interactions 
between scaffold, growth factors and cells. Growth factors 
are molecules which regulate cellular metabolism. They 
have an anabolic effect on tendon and ligament tissues 
through stimulation of cell proliferation, increase of 
extracellular matrix synthesis and promotion of vascular 
invasion. They also down-regulate catabolic matrix 
degradation cytokines e.g. matrix-metalloproteinases and 
interleukins [3]. Platelet rich plasma (PRP), an established 
growth factor enhanced therapy strategy, is a concentrate of 
platelets which release growth factors, including platelet- 
derived growth factor, transforming growth factor-β, 
insulin-like growth factor I, epidermal growth factor, 
vascular endothelial growth factor and fibroblast growth 
factor from the platelet α-granules [4,11,15].
The data obtained in this clinical case study are based on 
a small number of horses used for various disciplines 
(racing, pleasure riding, dressage or show jumping) referred 
for various tendon and ligament lesions. The regenerative 
therapy method of intralesional injection of ACP was chosen 
based on the encouraging results with PRP and bone 
marrow- ACP treatments in equine orthopaedics [2,7]. The 
data obtained in this case-study are encouraging and reveal 
that there could be remarkable positive changes in the early 
stages of injury healing, expressed by %MIZ, CSA, ES and 
FAS, of both tendinitis and desmitis if defect areas are 
directly treated with ACP. Partly, these effects could be 
explained with a coincidence with conditions and phases of 
normal tendon healing. Nevertheless, our data reflect cases Autologous conditioned plasma as therapy of tendon and ligament lesions in seven horses    175
of severe tendon lesions with %MIZ values greater than 
25%; such values are associated with a poor prognosis [13]. 
All seven horses, with lesions of the SDFT, DDFT and ICL, 
had %MIZ values far higher than this critical value but 
nevertheless underwent good recoveries. Horse SDFT 2 
showed sufficient healing of the SDFT lesion at D1. The 
horse received a second ACP-injection at D1 and had a 
subsequent deterioration of tendon structure and texture at 
D2 (Figs. 1 and 2). Nevertheless the horse recovered 
completely within five months. The described case underlines 
the fact that a repetitive intralesional ACP- injection has to 
be evaluated critically. Follow-up data of the horses described 
in this clinical case report − performed by interviewing the 
owners, trainers and/or referring veterinarians − revealed 
a positive outcome at 7 to 9 months as well as in an 
intermediate time range (10 to 13 months post injury, D3). 
All horses treated with ACP were either performing at their 
previous work-load or were back in full training. None of 
the horses treated with ACP showed signs of re-injury. These 
findings are consistent with those of another study in which 
40% of bone marrow-ACP treated horses were sound and 
60% of treated forelimbs showed an ultrasonographic 
improvement within four to six weeks [7]. Recent 
investigations into the biochemical, biomechanical and 
histological properties of tendons treated intralesionally 
with PRP in a placebo-controlled experimental study reflected 
a positive outcome of PRP-therapy after 24 weeks [3]. 
The ACP platelet count was 1.3-fold higher than that of 
whole blood. In contrast, PRP platelet counts have been 
found to be equal to or higher (range: 1.3- to 13.1-fold) than 
that of whole blood [9,11,16]. The ACP preparation used in 
this study had a mean 10.92-fold decrease in WBC counts 
compared to whole blood. In comparison, PRP preparations 
have shown either a lower decrease (mean 1.85-fold) or an 
increase in mononuclear cell concentration compared to 
whole blood [1,9,15,16]. Autologous conditioned plasma 
− in contrast to PRP − might therefore be less likely to 
increase disturbing inflammatory tissue reactions due to 
WBCs during regenerative therapy.
In conclusion, the limitations of this intermediate-term 
clinical study are the small number of horses included, their 
heterogenic use and breed and the variability of the tendon 
and ligament lesions treated with ACP. Further studies with 
a homogenous horse population and injury profiles, as well 
as long-term follow-up, need to be performed to strengthen 
these clinical observations.
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